メチシリン耐性黄色ブドウ球菌(MRSA)感染症:治療薬開発パイプライン動向(2016年下半期版)

◆英語タイトル:Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2016
◆商品コード:DATA70209208
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2016年11月16日
◆ページ数:421
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥214,000見積依頼/購入/質問フォーム
Site LicenseUSD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
Enterprisewide (Global Site License)USD6,000 ⇒換算¥642,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界におけるメチシリン耐性黄色ブドウ球菌(MRSA)感染症の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・メチシリン耐性黄色ブドウ球菌(MRSA)感染症の概要
・メチシリン耐性黄色ブドウ球菌(MRSA)感染症治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・メチシリン耐性黄色ブドウ球菌(MRSA)感染症パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・メチシリン耐性黄色ブドウ球菌(MRSA)感染症治療薬開発に取り組んでいる企業:企業別製品パイプライン
・メチシリン耐性黄色ブドウ球菌(MRSA)感染症治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline Review, H2 2016

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline Review, H2 2016, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline landscape.

MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections. Risk factors are hemodialysis, weakened immune system, admission to hospitals and wounds. Symptoms include skin rashes, fatigue, chest pain, fever and swelling. MRSA can be managed by the use of antibiotics and by maintaining hygienic conditions.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 10, 12, 72, 33 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 21 and 22 molecules, respectively.Methicillin-Resistant Staphylococcus aureus (MRSA) Infections.

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
Introduction 7
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Overview 8
Therapeutics Development 9
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Therapeutics under Development by Companies 11
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Therapeutics under Investigation by Universities/Institutes 18
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline Products Glance 20
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Products under Development by Companies 24
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Products under Investigation by Universities/Institutes 33
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Companies Involved in Therapeutics Development 36
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Therapeutics Assessment 126
Drug Profiles 138
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects 380
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Discontinued Products 388
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Product Development Milestones 389
Appendix 401

List of Tables
Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H2 2016 28
Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Comparative Analysis, H2 2016 29
Number of Products under Development by Companies, H2 2016 30
Number of Products under Development by Companies, H2 2016 (Contd..1) 31
Number of Products under Development by Companies, H2 2016 (Contd..2) 32
Number of Products under Development by Companies, H2 2016 (Contd..3) 33
Number of Products under Development by Companies, H2 2016 (Contd..4) 34
Number of Products under Development by Companies, H2 2016 (Contd..5) 35
Number of Products under Development by Companies, H2 2016 (Contd..6) 36
Number of Products under Investigation by Universities/Institutes, H2 2016 37
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 38
Comparative Analysis by Late Stage Development, H2 2016 39
Comparative Analysis by Clinical Stage Development, H2 2016 40
Comparative Analysis by Early Stage Development, H2 2016 41
Comparative Analysis by Unknown Stage Development, H2 2016 42
Products under Development by Companies, H2 2016 43
Products under Development by Companies, H2 2016 (Contd..1) 44
Products under Development by Companies, H2 2016 (Contd..2) 45
Products under Development by Companies, H2 2016 (Contd..3) 46
Products under Development by Companies, H2 2016 (Contd..4) 47
Products under Development by Companies, H2 2016 (Contd..5) 48
Products under Development by Companies, H2 2016 (Contd..6) 49
Products under Development by Companies, H2 2016 (Contd..7) 50
Products under Development by Companies, H2 2016 (Contd..8) 51
Products under Investigation by Universities/Institutes, H2 2016 52
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 53
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 54
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Absynth Biologics Limited, H2 2016 55
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Actelion Ltd, H2 2016 56
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Adenium Biotech ApS, H2 2016 57
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by AIMM Therapeutics B.V., H2 2016 58
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Alchemia Limited, H2 2016 59
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Allergan Plc, H2 2016 60
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by AlphaMab Co., Ltd, H2 2016 61
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Alvogen Korea Co., Ltd., H2 2016 62
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by AmpliPhi Biosciences Corporation, H2 2016 63
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by AnGes MG, Inc., H2 2016 64
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Antibiotx ApS, H2 2016 65
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Aphios Corporation, H2 2016 66
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Aridis Pharmaceuticals LLC, H2 2016 67
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Arsanis, Inc., H2 2016 68
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by AstraZeneca Plc, H2 2016 69
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Atriva Therapeutics GmbH, H2 2016 70
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Bavarian Nordic A/S, H2 2016 71
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Bharat Biotech International Limited, H2 2016 72
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by C3 Jian, Inc, H2 2016 73
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Cellceutix Corporation, H2 2016 74
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Cempra Inc, H2 2016 75
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Citius Pharmaceuticals, Inc., H2 2016 76
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Common Pharma Inc, H2 2016 77
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by ContraFect Corporation, H2 2016 78
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Crestone, Inc., H2 2016 79
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Critical Outcome Technologies Inc, H2 2016 80
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by CrystalGenomics, Inc., H2 2016 81
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by CSA Biotechnologies LLC , H2 2016 82
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Debiopharm International SA , H2 2016 83
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Dermala Inc, H2 2016 84
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by DesignMedix, Inc., H2 2016 85
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Destiny Pharma Limited, H2 2016 86
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016 87
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by e-Therapeutics Plc, H2 2016 88
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Emergent BioSolutions Inc., H2 2016 89
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Ensol Biosciences Inc., H2 2016 90
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Excelimmune, Inc., H2 2016 91
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Galapagos NV, H2 2016 92
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by GangaGen Inc., H2 2016 93
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Gero Corp, H2 2016 94
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Helix BioMedix, Inc., H2 2016 95
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Hsiri Therapeutics LLC, H2 2016 96
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Ildong Pharmaceutical Co., Ltd., H2 2016 97
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Immupharma Plc, H2 2016 98
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by iNtRON Biotechnology Inc., H2 2016 99
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by ioGenetics, Inc., H2 2016 100
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 101
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Lascco SA, H2 2016 102
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by LegoChem Biosciences, Inc, H2 2016 103
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Lipocure Ltd., H2 2016 104
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Madam Therapeutics B.V., H2 2016 105
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Melinta Therapeutics, Inc, H2 2016 106
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Merck & Co., Inc., H2 2016 107
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Microbiotix, Inc., H2 2016 108
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by MicuRx Pharmaceuticals, Inc., H2 2016 109
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by MorphoSys AG, H2 2016 110
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Motif Bio Plc, H2 2016 111
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Nabriva Therapeutics AG, H2 2016 112
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Nemus Bioscience, Inc., H2 2016 113
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Novabiotics Limited, H2 2016 114
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by NovaDigm Therapeutics, Inc., H2 2016 115
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by NovoBiotic Pharmaceuticals, LLC, H2 2016 116
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Omnia Molecular Ltd., H2 2016 117
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Oragenics, Inc., H2 2016 118
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Pfizer Inc., H2 2016 119
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Phico Therapeutics Limited, H2 2016 120
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Procarta Biosystems Limited, H2 2016 121
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Prommune, Inc., H2 2016 122
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Recce Pty Ltd, H2 2016 123
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Redx Pharma Plc, H2 2016 124
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Sarepta Therapeutics, Inc., H2 2016 125
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Savara Inc., H2 2016 126
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Sealife PHARMA GMBH, H2 2016 127
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Sentinella Pharmaceuticals, Inc., H2 2016 128
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Sequoia Sciences Inc, H2 2016 129
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Soligenix, Inc., H2 2016 130
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Sorrento Therapeutics Inc, H2 2016 131
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Taejoon Pharm Co., Ltd., H2 2016 132
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by TAXIS Pharmaceuticals, Inc., H2 2016 133
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Telephus Medical LLC, H2 2016 134
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Tetraphase Pharmaceuticals Inc., H2 2016 135
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by TGV-Laboratories, H2 2016 136
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Theravance Biopharma Inc, H2 2016 137
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Trellis Bioscience, Inc., H2 2016 138
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Valevia UK Limited, H2 2016 139
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by VLP Biotech, Inc., H2 2016 140
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Wintermute Biomedical LLC, H2 2016 141
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Wockhardt Limited, H2 2016 142
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by XBiotech Inc, H2 2016 143
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Yungjin Pharm. Co., Ltd., H2 2016 144
Assessment by Monotherapy Products, H2 2016 145
Assessment by Combination Products, H2 2016 146
Number of Products by Stage and Target, H2 2016 148
Number of Products by Stage and Mechanism of Action, H2 2016 151
Number of Products by Stage and Route of Administration, H2 2016 154
Number of Products by Stage and Molecule Type, H2 2016 156
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects, H2 2016 399
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects (Contd..1), H2 2016 400
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects (Contd..2), H2 2016 401
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects (Contd..3), H2 2016 402
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects (Contd..4), H2 2016 403
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects (Contd..5), H2 2016 404
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects (Contd..6), H2 2016 405
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects (Contd..7), H2 2016 406
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Discontinued Products, H2 2016 407

List of Figures
Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H2 2016 28
Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Comparative Analysis, H2 2016 29
Number of Products under Development by Companies, H2 2016 30
Number of Products under Investigation by Universities/Institutes, H2 2016 37
Comparative Analysis by Clinical Stage Development, H2 2016 40
Comparative Analysis by Early Stage Products, H2 2016 41
Assessment by Monotherapy Products, H2 2016 145
Assessment by Combination Products, H2 2016 146
Number of Products by Top 10 Targets, H2 2016 147
Number of Products by Stage and Top 10 Targets, H2 2016 147
Number of Products by Top 10 Mechanism of Actions, H2 2016 150
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 150
Number of Products by Top 10 Routes of Administration, H2 2016 153
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 153
Number of Products by Top 10 Molecule Types, H2 2016 155
Number of Products by Stage and Top 10 Molecule Types, H2 2016 155

【レポートのキーワード】

メチシリン耐性黄色ブドウ球菌(MRSA)感染症

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[メチシリン耐性黄色ブドウ球菌(MRSA)感染症:治療薬開発パイプライン動向(2016年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆